Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138653 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT05138653 is a Phase 1 study of Healthy Participants that has completed, run by Cerevel Therapeutics. The registered enrollment target is 73 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05138653, a Phase 1 study of Healthy Participants, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 2-part, double-blind, randomized, placebo-controlled, first-in-human trial evaluating a single ascending dose (4-way crossover, Part A) and multiple ascending doses (Part B) of CVL-354.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVL-354
Study Locations (1)
Texas
- Labcorp Drug Development - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2023-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05138653
The ClinicalTrials.gov registry entry for NCT05138653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher). The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05138653 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05138653 about?
NCT05138653 is a clinical study titled "A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants". This is a 2-part, double-blind, randomized, placebo-controlled, first-in-human trial evaluating a single ascending dose (4-way crossover, Part A) and multiple ascending doses (Part B) of CVL-354.
What is the current status of trial NCT05138653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2021-10-18. Estimated completion is 2023-01-23.
What conditions does trial NCT05138653 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT05138653?
The interventions under investigation include: Placebo (DRUG), CVL-354 (DRUG).
Who is sponsoring clinical trial NCT05138653?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05138653 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.